Investigational drug · Phase 3
ALKS 2680
Also called: Alixorexton
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
5 still active
All registered trials
7
Any phase or sponsor naming "ALKS 2680"
First trial start
2024
Mar 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALKS 2680", any sponsor or status.
Conditions studied
As listed on its trial records.
- Narcolepsy Type 1
- Narcolepsy Type 2
- Idiopathic Hypersomnia
Approved drugs for the same conditions: Narcolepsy · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALKS 2680" as an intervention, largest first.
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT06767683 · 786 participants (planned) · Start Jan 27, 2025 · Primary completion Jun 2030
Drug: ALKS 2680, 4mg; ALKS 2680, 6mg and 4 more · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Cullman, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 50 sites in all
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07502443 · 176 participants (planned) · Start Apr 22, 2026 · Primary completion May 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 2 more · For: Narcolepsy Type 2
Sites: Cullman, Alabama; Phoenix, Arizona; Los Angeles, California · 61 sites in all
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07540897 · 150 participants (planned) · Start Aug 13, 2026 · Primary completion Jun 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 1 more · For: Narcolepsy Type 1
Sites: Scottsdale, Arizona; Brandon, Florida; Miami, Florida · 53 sites in all
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07455383 · 150 participants (planned) · Start Apr 6, 2026 · Primary completion May 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 1 more · For: Narcolepsy Type 1
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 66 sites in all
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaPivotal-lookingActive, not recruiting
Alkermes, Inc.Industry
NCT06843590 · 126 participants (planned) · Start May 22, 2025 · Primary completion Nov 2026
Drug: ALKS 2680; Placebo · For: Idiopathic Hypersomnia
Sites: Cullman, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 50 sites in all
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2Completed
Alkermes, Inc.Industry
NCT06555783 · 93 participants · Start Jul 26, 2024 · Primary completion Nov 11, 2025
Drug: ALKS 2680; Placebo · For: Narcolepsy Type 2
Sites: Little Rock, Arkansas; Los Angeles, California; Redwood City, California · 47 sites in all
Alkermes, Inc.Industry
NCT06358950 · 92 participants · Start Mar 24, 2024 · Primary completion Jun 19, 2025
Drug: ALKS 2680; Placebo · For: Narcolepsy Type 1
Sites: Los Angeles, California; Redwood City, California; San Francisco, California · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Short-Term Efficacy and Safety of Oral Selective Orexin-2 Receptor Agonists in Narcolepsy Type 1: An Updated Systematic Review and Meta-Analysis of Randomized Trials.
Ali A, Sajjad A, Talha M, et al. · Neuropsychopharmacol Rep 2026
- Efficacy and safety of selective orexin 2 receptor agonists in narcolepsy type 1: a systematic review and meta-analysis of randomized controlled trials.
Yuan L, Huang YB, Chen YX, et al. · J Neurol 2026
- Orexin-2 Receptor Agonists in Narcolepsy: Restoring the Missing Signal.
Alzahrani YA, Harbi MH · J Clin Med 2026
- Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Plazzi G, Grunstein RR, Mignot E, et al. · Lancet Neurol 2026
- Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof-Of-Concept Study of Alixorexton.
Grunstein RR, Yee BJ, Chapman JL, et al. · J Sleep Res 2026
Also in development for Narcolepsy Type 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.